Latrepirdine
- Generic Name
- Latrepirdine
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C21H25N3
- CAS Number
- 3613-73-8
- Unique Ingredient Identifier
- OD9237K1Z6
- Background
Latrepirdine has been investigated for the treatment of Alzheimer's Disease and Huntington's Disease.
- Associated Conditions
- -
- Associated Therapies
- -
Alzheimer's disease drug-development pipeline: few successes amidst high attrition rates
Analysis of clinicaltrials.gov reveals high attrition rates in Alzheimer's disease (AD) drug development, with only 0.4% success rate for approval. Disease-modifying agents face longer trial durations and higher resource demands than symptomatic treatments. Despite 244 compounds tested from 2002-2012, only one symptomatic cognitive enhancer was approved. Current AD drug development is challenged by high failure rates, necessitating new approaches and better trial strategies to improve success.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath